Skip to main content

Autologous Fat Injection (AFI) — Penile Girth Enhancement

Autologous fat injection (AFI) for penile girth enhancement is one of the oldest and most widely performed penile-augmentation techniques, first popularized in the early 1990s. It involves harvesting fat via liposuction from a donor site and injecting it subcutaneously around the penile shaft. While the procedure offers biocompatibility and a natural feel, it is plagued by unpredictable fat resorption (20–80%), irregular nodule formation, and penile deformity, which have made it one of the most controversial techniques in genital cosmetic surgery.[1][2][3][4]

For the broader male cosmetic-genital-surgery decision framework see the Male Cosmetic Genital Surgery atlas page. For the related dermal-fat-graft variant + ADM wraps see Dermal Fat Grafts & AlloDerm Wraps. For the canonical reversible alternative see Hyaluronic Acid Filler.

I. Definition and Concept​

Autologous fat injection (autologous fat transfer, lipofilling, fat grafting) for penile girth enhancement involves three sequential steps.[1][5][6]

  1. Harvesting — fat aspirated from a donor site (abdomen, flanks, thighs) via liposuction.
  2. Processing — lipoaspirate refined (centrifugation, decanting, or filtration) to separate viable adipocytes from blood, oil, and debris.
  3. Injection — purified fat injected into the subcutaneous tissue of the penile shaft (between skin / dartos fascia and Buck's fascia) to increase circumference.

The fundamental appeal is that autologous fat is biocompatible, non-immunogenic, readily available, and natural-feeling.[7] However, the penis is a uniquely challenging recipient site because of its mobile, thin-skinned, cylindrical anatomy with a limited vascular bed for graft revascularization, and the constant mechanical stress of erection / detumescence cycles.[1][3]

II. Historical Context​

  • Early 1990s — penile fat injection popularized alongside SLD as a combined "penile enlargement" procedure, heavily marketed.[2][3]
  • 1994 — Trockman first case report of complications (painful inflammatory nodules requiring excision).[8]
  • 1996 — Wessells, Lue & McAninch UCSF landmark referral-center complication series (12 patients, 10 with fat injection complications) — irregular fat nodules 7/10, skin deformity 4/10, reoperation 6/10, sexual dysfunction 4/10. Authors' verdict: techniques "should be regarded as experimental."[2]
  • 1997 — Alter definitive series on reconstruction of deformities, describing "disappearance of fat, penile lumps and nodules, and shaft deformities" as the hallmark complications.[3]
  • 2000s–present — refined techniques (multi-layer injection, smaller volumes, Coleman principles) improved outcomes in select series, but unpredictable fat resorption persists.[1][9][10]

III. Surgical Technique​

A. Fat harvesting​

Donor sites (in order of preference).[1][5][6]

  • Abdomen — most commonly used; convenient; large volume.
  • Flanks / love handles — good fat quality.
  • Inner thighs — when abdominal fat is insufficient.
  • Buttocks — less commonly used.

Harvesting method.[5][6][11]

  • Suction-assisted liposuction (SAL) — standard; tumescent solution (lidocaine + epinephrine in saline) infiltrated, then aspirated through a blunt-tipped cannula.
  • Syringe aspiration (Coleman technique) — manual aspiration via 10 mL syringes attached to a blunt cannula; gentler on adipocytes.[6]
  • Cannula size matters — larger harvesting cannulas (≥ 3 mm) reduce shearing and improve viability.[5]
  • Low negative pressure — excessive suction damages adipocytes; gentle controlled aspiration preferred.[5]

B. Fat processing[5][6][11]​

  1. Centrifugation (Coleman) — 1,200g × 3 min; three layers (oil top / concentrated fat middle / blood-fluid bottom). Middle layer used for injection. Most widely standardized method.[6][11]
  2. Decanting / gravity sedimentation — simpler but less consistent.[5]
  3. Cotton-pad filtration — may preserve adipocyte structure better than centrifugation.[11]
  4. Soft centrifugation — 400g × 1 min; compromise between concentration and viability.[11]

Key principle. Protecting adipose-tissue structure and viability throughout processing is crucial — greater structural damage is associated with poorer graft quality (decreased viability, vessel density, increased vacuoles, necrosis, fibrosis, inflammation) even when volume retention rates are similar.[11]

C. Injection technique (penile-specific)​

Kang 2012 (n = 52) — most detailed published technique for penile fat injection.[1]

  • Injection plane — Colles' fascia (dartos fascia), the subcutaneous layer between penile skin and Buck's fascia.
  • Multi-layer injection — superficial, middle, and deep layers of Colles' fascia for even distribution.
  • Entry points — 2–4 small stab incisions at the penile base or along the shaft.
  • Injection volume — mean 38.54 mL (range 25–49 mL).
  • Technique — small aliquots in a retrograde, fanning pattern with a blunt-tipped cannula; penis held in traction.
  • Circumferential distribution — even around the entire circumference to avoid asymmetry.
  • Operative time — mean 44 minutes (range 37–49 min).

Critical technical principles (general fat-grafting literature).[5]

  • Small aliquots (0.1–0.5 mL per pass) maximize surface-area contact with recipient tissue for revascularization.
  • Avoid pooling — large bolus deposits undergo central necrosis from inadequate diffusion.
  • Slow injection speed reduces shearing.
  • Blunt-tipped cannulas avoid intravascular injection and reduce trauma.[5]
  • Avoid injection into Buck's fascia or tunica albuginea — risk of ED, Peyronie's-like fibrosis, or corporal injury.

IV. Outcomes​

StudynVolume injectedGirth gainLength effectComplicationsFollow-up
Kang 2012[1]5238.5 mL (25–49)+2.28 cm proximal; +2.28 cm distalNo changeNodular fat 1.92%6 mo
Deskoulidi & Caminer 2023[9]75Not specified~ 1 cmCombined with SLD (2–4 cm length)3 revisions (4%)Variable
Salem 2019[10]30Not specifiedSignificant increaseN/AFat loss at 6 mo6 mo
Spyropoulos 2005 (dermal-fat graft)[12]3N/A+2.3–2.6 cm+1.6 cm (with SLD)Minor; 91% improved sexual self-esteemVariable
Wessells 1996 (referral complications)[2]10Not specified—Only 1/12 reported length gainNodules 70%, deformity 40%, reoperation 50%, sexual dysfunction 33%16 mo
Alter 1997 (reconstruction)[3]19———Fat disappearance, lumps, nodules, shaft deformities—

V. The Central Problem — Unpredictable Fat Resorption​

The fundamental limitation of AFI — in the penis and at all body sites — is unpredictable and often substantial graft resorption.[4][7][13][14]

General fat-grafting resorption data​

  • Resorption rate 20–80% of injected volume, depending on technique, recipient site, and patient factors.[7][13]
  • Pooled facial-fat-graft retention 47% (95% CI 41–53%) at 3–24 months (meta-analysis, 27 studies, 1,011 patients).[4]
  • Conventional fat-grafting survival ~ 44% (vs ~ 64% with cell-assisted lipotransfer).[13]

Penile-specific resorption concerns​

  • The penis is a uniquely hostile recipient site because of:
    • Thin subcutaneous tissue with limited vascular bed.
    • Constant mechanical stress from erection / detumescence cycles.
    • Mobile anatomy — significant dimensional changes with erection.
    • Gravity-dependent position — fat may migrate or redistribute unevenly.
  • Salem 2019 specifically noted "fat loss at 6 months" in their penile fat-injection series.[10]
  • Alter 1997 described "disappearance of fat" as one of the three cardinal complications of penile fat injection.[3]
  • Resorption is non-uniform — some areas resorb more than others, leading to the characteristic irregular nodularity and asymmetry that defines the complication profile.[2][3]

VI. Complications​

A. Irregular fat nodules and lumps — the hallmark complication[1][2][3][8]​

  • Wessells 1996 — 7/10 (70%) patients with fat injection had "irregular residual fat nodules" as their chief complaint.[2]
  • Alter 1997 — described "penile lumps and nodules" as a primary indication for reconstructive surgery.[3]
  • Trockman 1994 — first case report; 2 painful inflammatory nodules requiring surgical excision 3 months post-injection.[8]
  • Kang 2012 — only 1/52 (1.92%) nodular fat — notably lower rate, possibly reflecting improved technique (multi-layer injection).[1]

Mechanism. Non-uniform fat resorption leaves islands of surviving fat interspersed with areas of complete resorption, creating palpable and visible irregularities. Large bolus deposits undergo central necrosis, forming oil cysts and calcified nodules.[3][5]

B. Penile deformity and poor cosmetic appearance​

  • Wessells — "poor cosmetic appearance" was the chief complaint in all 12 referral patients.[2]
  • Skin deformity / scarring 4/12.
  • Scrotalization 4/12 — fat migrating into scrotal skin.
  • Shaft deformities — asymmetric thickening, irregular contour, "sausage-like" or "lumpy" appearance.[3]

C. Fat disappearance / resorption​

  • Complete or near-complete resorption leaving the patient with no girth gain and potentially worse cosmesis than baseline (from scarring and fibrosis).[3]
  • The most frustrating outcome — surgery with no lasting benefit.

D. Sexual dysfunction​

  • Wessells — 4/12 (33%) patients reported sexual dysfunction.[2]
  • Mechanisms — pain from nodules during intercourse, altered penile sensation, psychological distress from deformity, rarely ED from deep injection injury.

E. Wound complications​

  • Wessells — 6/12 (50%) wound complications.[2]
  • Infection, hematoma, seroma at injection sites or donor sites.

F. Need for reoperation​

  • Wessells — 6/12 (50%) required reoperation.[2]
  • Deskoulidi — 3/75 (4%) revision.[9]
  • Alter — 19 patients underwent 24 reconstructive operations for deformities from penile-enlargement surgery.[3]

G. Fat necrosis and oil cysts​

  • Large deposits of injected fat that fail to revascularize undergo liquefactive necrosis, forming oil cysts (sterile collections of liquefied fat).
  • May calcify over time into palpable hard nodules.
  • Can be confused with malignancy on imaging.

H. Infection​

  • Rare but reported; superficial cellulitis to deep abscess. Risk increased with non-sterile technique or excessive tissue trauma.

VII. Reconstruction of Fat-Injection Complications​

Alter 1997 described the definitive approach.[3]

  • Fat-nodule excision through small incisions.
  • Asymmetrical fat-deposit removal (debulking).
  • Scar revision for injection-site scars.
  • Limitations — complete correction not always possible; some residual deformity may persist.
  • Penile appearance and function improved in all 19 reconstruction patients.

Furr 2018 referral-center series — 11 patients with severe complications from genital-enlargement surgery (including AFI), with adverse changes including "sexually disabling penile deformity and severe shortening, curvature, edema, subcutaneous masses, infection, non-healing wounds, and sexual dysfunction." 10/11 underwent corrective surgery, 3 with split-thickness skin grafting.[15]

For the operative atlas of these reconstructions see Penile Skin / Shaft Reconstruction (04e).

VIII. Strategies to Improve Fat-Graft Survival​

Several enrichment strategies have been investigated, though none have been specifically studied for penile fat grafting.

A. Platelet-rich plasma (PRP)​

  • Wu 2021 meta-analysis (11 studies, 1,125 patients) — PRP + fat grafting showed significantly higher fat-survival rate and lower recovery time vs conventional fat grafting; no difference in patient satisfaction.[16]
  • Fat survival 20.5–54.8% (FG alone) vs 24.1–89.2% (PRP + FG).[16]
  • PRP and SVF / ADSCs are the "most promising approaches" for fat-graft enrichment.[17]

B. Stromal vascular fraction (SVF)​

  • Jefri 2026 meta-analysis (18 studies, 893 patients) — SVF-enriched fat grafting demonstrated significantly higher fat retention (mean difference +17.20%, 95% CI 11.26–23.15, p < 0.001).[18]
  • Automated enzymatic SVF preparation achieved the highest retention gains (+22.8%).[18]
  • No increase in complications (cyst / fat-necrosis rates comparable).[18]

C. Cell-assisted lipotransfer (CAL) / adipose-derived stem cells (ADSCs)​

  • Laloze 2018 meta-analysis (25 studies, 696 patients) — CAL showed significantly higher fat survival than conventional grafting (64% vs 44%, p < 0.05).[13]
  • Benefit significant only for injection volumes > 100 mL.[13]
  • However CAL was associated with more complications (8.4% vs 1.5%, p = 0.0019) and did not reduce the number of procedures needed.[13]

D. Technical optimization (Nemir 2021)[5]​

  • Larger harvesting / grafting cannulas — reduce shearing.
  • Slow injection speeds — minimize cell damage.
  • Dispersion technique — small aliquots distributed throughout tissue, avoiding pooling.
  • Minimize environmental exposure during processing.
  • Blunt-tipped cannulas — avoid intravascular injection.
  • Gentle processing (soft centrifugation or filtration) may preserve adipocyte structure better than standard Coleman centrifugation.[11]

Important caveat. None of these enrichment strategies have been specifically evaluated in penile fat grafting. The unique biomechanical environment of the penis (erection / detumescence cycles, thin subcutaneous tissue) may limit the applicability of data from facial and breast fat grafting.

IX. Comparison With Other Girth-Enhancement Techniques​

FeatureAutologous fat injectionHA fillerDermal fat graftPenuma silicone implant
MaterialPatient's own fatCross-linked HAPatient's dermal-fat stripMedical-grade silicone (cured)
BiocompatibilityExcellent (autologous)Good (biodegradable)Excellent (autologous)Good (inert)
Girth gain1–2.3 cm (variable)1.7–3.4 cm1.5–2.6 cm4.9 cm (+56.7%)
DurabilityUnpredictable (20–80% resorption)12–24 months (resorbable)More durable than fat injectionPermanent (until removal)
ReversibilityPartially (nodule excision)Yes (hyaluronidase)Partially (surgical removal)Yes (surgical removal)
Nodule / irregularity rateHigh (up to 70% in referral series)Low (~ 4%)LowLow (but migration possible)
Reoperation rateHigh (4–50%)Low (touch-up injections)Low3–10% removal
InvasivenessModerate (liposuction + injection)Minimally invasive (office)Surgical (donor site + penile)Surgical (implant placement)
FDA statusNo FDA approval for penile useNo FDA approval for penile useNo FDA approval for penile useFDA 510(k) cleared (Penuma)

X. Special Application — Fat Injection With Penile Prosthesis ("Girth Supersizing")​

Salem 2019 described a unique application — autologous fat injection combined with semi-rigid penile-prosthesis insertion for "girth supersizing" in patients with ED.[10]

  • n = 30 (15 prosthesis + fat injection, 15 fat injection alone).
  • Median penile girth increased significantly in both groups.
  • Fat loss noted at 6 months — confirming resorption occurs even with the structural support of a prosthesis.
  • Positive correlation between volume injected and girth change at 6 months.
  • Authors concluded fat transfer is "simple and safe" for patients with girth dissatisfaction undergoing prosthesis insertion.

XI. Patient Selection and Contraindications​

Appropriate candidates (based on published series).[1][12]

  • Men with objectively thin penises (Kang selected patients with circumference ≤ 7.4 cm).[1]
  • Men with penile dysmorphophobia who have undergone psychological screening and have realistic expectations.[12]
  • Adequate donor-site fat for harvesting.
  • Psychosomatically normal individuals (Spyropoulos excluded patients with psychiatric disorders).[12]

Relative contraindications.

  • Unrealistic expectations — patients expecting dramatic, permanent girth increase.
  • Body dysmorphic disorder (BDD) — formal psychiatric evaluation recommended before any augmentation procedure.[19]
  • Insufficient donor-site fat — very lean patients.
  • Active penile infection or skin disease.
  • Coagulopathy or anticoagulant use (relative, for liposuction component).
  • Prior penile surgery with significant scarring (may limit injection plane).

Psychological screening. Multiple authors emphasize that "most men seeking these interventions have penile dimensions within the normal range" and recommend a multidisciplinary approach including psychological evaluation.[12][19] Spyropoulos used a structured questionnaire to select only 11 of 28 presenting patients (39%) for surgery.[12]

XII. Evidence Quality and Limitations​

The evidence base for penile AFI is limited and of low quality.[21][22][23]

  • No randomized controlled trials for penile fat injection.
  • The largest prospective series (Kang n = 52) had only 6 months of follow-up — insufficient to capture long-term resorption.[1]
  • Most informative data come from referral-center complication series (Wessells, Alter, Furr) which inherently overrepresent complications but provide critical safety data.[2][3][15]
  • 89.7% of all penile-girth-enhancement studies are non-RCTs with "overall low quality and limited level of evidence."[21]
  • Romero-Otero 2021 BJU Int SR — "the quality of studies on penile-enhancement procedures is still low" and "prevents us from establishing recommendations based on scientific evidence."[22]
  • Vyas 2020 SR — "poor" study quality regarding methodology for patient selection and outcomes reporting; pooled complication rate 14.6% across all augmentation techniques.[23]
  • Adverse events are probably largely under-reported across all penile-augmentation studies.[21]

XIII. Clinical Summary​

Autologous fat injection for penile girth enhancement is a historically significant but deeply flawed technique. The procedure offers theoretical advantages of biocompatibility, natural feel, and simultaneous body contouring at the donor site. However, unpredictable fat resorption (20–80%) and the high incidence of irregular nodularity, penile deformity, and need for reoperation — documented in referral-center series at rates of 50–70% — have led most experts to view it with significant caution.[2][3][15]

More recent series using refined multi-layer injection techniques (Kang n = 52) report dramatically lower complication rates (1.92% nodule rate) and significant girth gains (+2.28 cm at 6 months) — suggesting that technique matters enormously.[1] Similarly, Deskoulidi & Caminer (n = 75, 15 yr experience) report only a 4% revision rate with fat injection as part of combined augmentation.[9]

The critical unresolved question is long-term durability — most series report only 6-month outcomes, and fat resorption may continue beyond this timeframe.[4][10] Enrichment strategies (PRP, SVF, ADSCs) show promise for improving fat-graft survival in other body sites but have not been studied for penile application.[16][17][18]

Compared to hyaluronic acid fillers, fat injection offers potential permanence at the cost of greater invasiveness, unpredictability, and higher complication rates. HA fillers provide more predictable, uniform results with the safety net of reversibility (hyaluronidase), though they require repeat injections every 12–24 months.[20][21] The choice between techniques should be individualized based on patient anatomy, expectations, and tolerance for the respective risk profiles.

See Also​

References​

1. Kang DH, Chung JH, Kim YJ, et al. Efficacy and safety of penile-girth enhancement by autologous fat injection for patients with thin penises. Aesthet Plast Surg. 2012;36(4):813–818. doi:10.1007/s00266-012-9891-4

2. Wessells H, Lue TF, McAninch JW. Complications of penile lengthening and augmentation seen at one referral center. J Urol. 1996;155(5):1617–1620.

3. Alter GJ. Reconstruction of deformities resulting from penile-enlargement surgery. J Urol. 1997;158(6):2153–2157. doi:10.1016/s0022-5347(01)68185-0

4. Lv Q, Li X, Qi Y, et al. Volume retention after facial fat grafting and relevant factors: a systematic review and meta-analysis. Aesthet Plast Surg. 2021;45(2):506–520. doi:10.1007/s00266-020-01612-6

5. Nemir S, Hanson SE, Chu CK. Surgical decision-making in autologous fat grafting: an evidence-based review of techniques to maximize fat survival. Aesthet Surg J. 2021;41(Suppl 1):S3–S15. doi:10.1093/asj/sjab080

6. Egro FM, Roy E, Rubin JP, Coleman SR. Evolution of the Coleman technique. Plast Reconstr Surg. 2022;150(2):329e–336e. doi:10.1097/PRS.0000000000009355

7. Kølle SF, Fischer-Nielsen A, Mathiasen AB, et al. Enrichment of autologous fat grafts with ex-vivo expanded adipose-tissue-derived stem cells for graft survival: a randomised placebo-controlled trial. Lancet. 2013;382(9898):1113–1120. doi:10.1016/S0140-6736(13)61410-5

8. Trockman BA, Berman CJ, Sendelbach K, Canning JR. Complication of penile injection of autologous fat. J Urol. 1994;151(2):429–430. doi:10.1016/s0022-5347(17)34972-8

9. Deskoulidi PI, Caminer D. Lengthening phalloplasty with division of the suspensory ligament and distally based fat flaps in penis-enlargement operations. Plast Reconstr Surg. 2023;152(3):434e–437e. doi:10.1097/PRS.0000000000010313

10. Salem AM, Osman IAL, Zaghloul AS, et al. Effect of girth supersizing on patient satisfaction after semi-rigid penile-implant insertion: a prospective case-control study. Aesthet Surg J. 2019;39(7):NP259–NP265. doi:10.1093/asj/sjz072

11. He Y, Zhang X, Han X, Li F. The importance of protecting the structure and viability of adipose tissue for fat grafting. Plast Reconstr Surg. 2022;149(6):1357–1368. doi:10.1097/PRS.0000000000009139

12. Spyropoulos E, Christoforidis C, Borousas D, et al. Augmentation phalloplasty surgery for penile dysmorphophobia in young adults: considerations regarding patient selection, outcome evaluation and techniques applied. Eur Urol. 2005;48(1):121–127. doi:10.1016/j.eururo.2005.02.021

13. Laloze J, Varin A, Gilhodes J, et al. Cell-assisted lipotransfer: friend or foe in fat grafting? Systematic review and meta-analysis. J Tissue Eng Regen Med. 2018;12(2):e1237–e1250. doi:10.1002/term.2524

14. Trotzier C, Sequeira I, Auxenfans C, Mojallal AA. Fat-graft retention: adipose tissue, adipose-derived stem cells, and aging. Plast Reconstr Surg. 2023;151(3):420e–431e. doi:10.1097/PRS.0000000000009918

15. Furr J, Hebert K, Wisenbaugh E, Gelman J. Complications of genital-enlargement surgery. J Sex Med. 2018;15(12):1811–1817. doi:10.1016/j.jsxm.2018.10.007

16. Wu M, Karvar M, Liu Q, Orgill DP, Panayi AC. Comparison of conventional and platelet-rich-plasma-assisted fat grafting: a systematic review and meta-analysis. J Plast Reconstr Aesthet Surg. 2021;74(11):2821–2830. doi:10.1016/j.bjps.2021.05.046

17. Hasiba-Pappas S, Opriessnig E, Nischwitz SP, et al. Optimizing autologous fat grafting: a systematic review of enhancement strategies and graft survival. Aesthet Surg J. 2025. doi:10.1093/asj/sjaf242

18. Jefri ZE, Alashjaee RH, Almarri AK, et al. Stromal-vascular-fraction-assisted fat grafting: a systematic review and meta-analysis of clinical outcomes. Aesthet Plast Surg. 2026;50(2):677–691. doi:10.1007/s00266-025-05511-6

19. Ramazan M, Øbro LF, Wiborg MH, et al. Complications of penile augmentation: a narrative review of injectables, implants, and surgical grafts. Int J Impot Res. 2026;38(3):238–246. doi:10.1038/s41443-025-01190-8

20. Oates J, Sharp G. Nonsurgical medical penile-girth augmentation: experience-based recommendations. Aesthet Surg J. 2017;37(9):1032–1038. doi:10.1093/asj/sjx068

21. Manfredi C, Romero Otero J, Djinovic R. Penile-girth-enhancement procedures for aesthetic purposes. Int J Impot Res. 2022;34(4):337–342. doi:10.1038/s41443-021-00459-y

22. Romero-Otero J, Manfredi C, Ralph D, et al. Non-invasive and surgical penile-enhancement interventions for aesthetic or therapeutic purposes: a systematic review. BJU Int. 2021;127(3):269–291. doi:10.1111/bju.15145

23. Vyas KS, Abu-Ghname A, Banuelos J, Morrison SD, Manrique O. Aesthetic augmentation phalloplasty: a systematic review of techniques and outcomes. Plast Reconstr Surg. 2020;146(5):995–1006. doi:10.1097/PRS.0000000000007249